Want to take quizzes and track your credits?
A woman in her 60s with a history of bilateral proliferative diabetic retinopathy complicated by a recent vitreous hemorrhage in her left eye presented with an acute onset of redness, irritation, and blurred vision in her left eye. Her symptoms started 1 day after she rubbed her left eye with her hands after handling the milky latex (a fluid found in 10% of flowering plants) of a plant in her garden. She had no recent history of recent eye surgery, eye trauma, cold sores, or new illnesses.
Please finish quiz first before checking answer.
Read the answer below and download your certificate.
Read the discussion below and retake the quiz.
Corneal endothelial toxicity secondary to Asclepias milkweed plant exposure
B. Start topical corticosteroid eyedrops
In this case, the patient’s corneal edema was secondary to direct exposure to a plant of the genus Asclepias (milkweed family), which is commonly found in the tropics, subtropics, grasslands, and gardens. Plants in the Asclepiadaceae family are known to contain cardiac glycosides in their latex, leaves, stems, and roots. Cardiac glycosides can inhibit the Na+-K+-ATPase enzyme found in the corneal endothelium and are able to penetrate the cornea with minimal injury to the corneal epithelium.1 Two previous cases have described isolated endothelial decompensation and stromal edema after exposure to the milky latex of Asclepias curassavica2 and Asclepias fruticose.3
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Audina Berrocal, MD, Bascom Palmer Eye Institute, University of Miami, 900 NW 17th St, Miami, FL 33136 (email@example.com).
Published Online: July 23, 2020. doi:10.1001/jamaophthalmol.2020.1325
Conflict of Interest Disclosures: Dr Berrocal reported personal fees from Alcon, PROQr, Novartis, Zeiss, Dutch Ophthalmic Research Center, and Allergan and nonfinancial support from Applied Genetic Technologies Corporation outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank the patient for granting permission to publish this information.
You currently have no searches saved.